{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-002051","form_type":"8-K","ticker":"SNOA","cik":"0001367083","company_name":"Sonoma Pharmaceuticals, Inc.","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.106197+00:00","generated_at":"2026-06-04T03:25:15.724226+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"confidence":"low","headline":"Sonoma Pharmaceuticals updates investor presentation; no material changes","bullets":["HOCl product portfolio covers wound, eye, oral, nasal, dermatology, podiatry, and animal health","Products sold in 55 countries via direct sales and distribution partners","No new financial guidance or material business developments in the presentation"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-002051","json":"https://secwatch.observer/filing/0001683168-24-002051.json","markdown":"https://secwatch.observer/filing/0001683168-24-002051.md","text":"https://secwatch.observer/filing/0001683168-24-002051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367083/000168316824002051/0001683168-24-002051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367083/000168316824002051/sonoma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:25:15.724226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}